Evidence for medical cannabis in palliative care remains inconclusive despite patient interest
A review of medicinal cannabinoids in palliative care found strong public support but inconclusive clinical data for key symptoms like pain and nausea, with findings from other settings not easily transferable.
Quick Facts
What This Study Found
The author examined the evidence base for using medicinal cannabinoids in people with palliative diagnoses, where treatments increasingly focus on symptom management earlier in the disease trajectory. Despite strong public support for cannabis availability in palliative care, the clinical evidence tells a more cautious story.
For key palliative symptoms like pain and nausea, clinical data has been inconclusive. The author specifically noted that data from chemotherapy-induced nausea and vomiting cannot be readily extrapolated to palliative care nausea, as the underlying mechanisms differ.
The review advocated for exploring medicinal cannabinoids within clinical trials to accelerate the evidence base. For patients with refractory symptoms where other treatments have failed, the author suggested that off-label prescribing should consider pharmacokinetic and pharmacodynamic interactions, drug-drug interactions, and include informed discussion with patients and regular review of whether the treatment is actually helping.
Key Numbers
No specific quantitative findings reported. The review assessed the quality of evidence across multiple symptom domains in palliative care.
How They Did This
This was a narrative review and clinical commentary examining the current evidence for medicinal cannabinoids in palliative care populations, with attention to the endocannabinoid system as a therapeutic target and practical considerations for prescribing.
Why This Research Matters
Palliative care patients have some of the most urgent needs for symptom relief, and many are interested in cannabis. This review provides a measured perspective that acknowledges the therapeutic potential while cautioning against assuming efficacy without adequate evidence. It bridges the gap between patient demand and clinical evidence.
The Bigger Picture
The disconnect between strong public support for medicinal cannabis in palliative care and the actual evidence base mirrors a broader challenge in cannabis medicine. Patients facing serious illness may be more willing to try unproven treatments, making it especially important that clinicians can offer evidence-based guidance.
What This Study Doesn't Tell Us
This is a narrative review and clinical commentary rather than a systematic review. The author's opinions, while informed, reflect a single expert perspective. The palliative care population is heterogeneous, and general conclusions may not apply to specific patients or conditions.
Questions This Raises
- ?Could well-designed palliative care trials produce different results than the mixed findings from other clinical settings?
- ?What is the appropriate balance between evidence requirements and compassionate access for people with limited time?
- ?How should drug-drug interactions between cannabinoids and common palliative medications be managed?
Trust & Context
- Key Stat:
- Clinical data for cannabis in palliative pain and nausea remains inconclusive
- Evidence Grade:
- This is a narrative review reflecting expert opinion on available evidence, providing moderate-level guidance.
- Study Age:
- Published in 2018. Palliative cannabis research has continued with several trials since.
- Original Title:
- Medicinal cannabinoids in palliative care.
- Published In:
- British journal of clinical pharmacology, 84(11), 2491-2494 (2018)
- Authors:
- Agar, Meera(2)
- Database ID:
- RTHC-01567
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with end-of-life symptoms?
The evidence is inconclusive. While there are areas where cannabinoids could theoretically help through the endocannabinoid system, clinical data for key palliative symptoms like pain and nausea has not shown consistent benefits. More research specifically in palliative populations is needed.
Can palliative patients try cannabis if nothing else works?
The review author suggests that for refractory symptoms, off-label cannabinoid prescribing can be considered, but should account for drug interactions, include informed patient discussion, and include regular assessment of whether it is actually providing benefit.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01567APA
Agar, Meera. (2018). Medicinal cannabinoids in palliative care.. British journal of clinical pharmacology, 84(11), 2491-2494. https://doi.org/10.1111/bcp.13671
MLA
Agar, Meera. "Medicinal cannabinoids in palliative care.." British journal of clinical pharmacology, 2018. https://doi.org/10.1111/bcp.13671
RethinkTHC
RethinkTHC Research Database. "Medicinal cannabinoids in palliative care." RTHC-01567. Retrieved from https://rethinkthc.com/research/agar-2018-medicinal-cannabinoids-in-palliative
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.